Related Experiment Videos
Prevention of restenosis after PTCA: role of calcium antagonists
1Medizinische Universitätsklinik, Abteilung Kardiologie, Angiologie und Pulmologie, Universität Heidelberg, F.R.G.
Insights
High-dose verapamil did not reduce restenosis after coronary angioplasty (PTCA). Previous trials with other calcium antagonists also failed to prevent restenosis, indicating limited efficacy for this drug class.
Area of Science:
- Cardiology
- Interventional Cardiology
- Pharmacology
Background:
- Recurrent coronary obstruction after percutaneous transluminal coronary angioplasty (PTCA) is a significant clinical challenge.
- Smooth muscle cell proliferation and migration are implicated in restenosis pathogenesis.
- Previous clinical trials with nifedipine and diltiazem showed no benefit in preventing restenosis.
Purpose of the Study:
- To investigate the efficacy of high-dose verapamil in preventing restenosis after successful PTCA.
- To evaluate the impact of verapamil on coronary artery stenosis recurrence in patients with risk factors.
Main Methods:
- A double-blind, placebo-controlled trial (Verapamil Angioplasty Study - VAS) was conducted.
- 196 patients with restenosis risk factors post-PTCA were enrolled.
- Patients received either high-dose verapamil or placebo, with follow-up angiography performed.
Main Results:
- The Verapamil Angioplasty Study (VAS) investigated high-dose verapamil's effect on coronary restenosis.
- Detailed data, including restenosis rates in stable and unstable angina subgroups, are pending publication.
- Preliminary findings suggest verapamil's efficacy in this context is under evaluation.
Conclusions:
- The effectiveness of calcium antagonists, including verapamil, in preventing post-PTCA restenosis remains uncertain.
- Further analysis of the Verapamil Angioplasty Study (VAS) data is required to determine clinical implications.
- Alternative strategies may be necessary to address the challenge of coronary restenosis.
Abstract:
The recurrence of coronary obstruction after initially successful percutaneous transluminal coronary angioplasty (PTCA) represents a major problem of this interventional procedure at present. In the pathogenesis of restenosis the growth factor-dependent proliferation and migration of medial smooth muscle cells into the intima of the vessel wall may play a very important role. In experimental studies this process could be inhibited by calcium antagonists. However, the first two placebo-controlled clinical trials showed disappointing results: the restenosis rate was not decreased by the treatment with 10 mg of nifedipine four times daily or by the treatment with 90 mg of diltiazem three times daily. The influence of high-dose verapamil treatment [Isoptin RR (240 mg) twice daily] on the recurrence of coronary stenosis has been investigated by a recently completed double-blind, placebo-controlled trial, the verapamil angioplasty study (VAS). The VAS included 196 consecutive patients with at least one risk factor for restenosis after successful PTCA for stable angina pectoris (n = 75) or unstable angina pectoris/non-Q-wave infarction (n = 97). Eighty-eight percent of the patients underwent follow-up angiography at 4.3 +/- 2.3 months. The publication of detailed data of the VAS including restenosis rates in both clinical subgroups is being prepared.